Truist Securities Maintains Hold on Immunovant, Raises Price Target to $22
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
Truist Securities analyst Danielle Brill maintains Immunovant (NASDAQ:IMVT) with a Hold and raises the price target from $16 to $22.
Truist Securities analyst Danielle Brill maintains Immunovant (NASDAQ:IMVT) with a Hold and raises the price target from $16 to $22.